Skip to main content

LCD L38331: MolDX: Blood Product Molecular Antigen Typing

LCD L38331, MolDX: Blood Product Molecular Antigen Typing, is the Local Coverage Determination that Noridian Healthcare Solutions, LLC applies to claims from 13 states plus 3 territories (AK, AS, AZ, CA, GU, HI, ID, MP and others), effective 2026-01-22 and first in force 2020-12-06. The policy text runs 335 words, and its billing and coding article A57124 lists 116 ICD-10-CM codes that support medical necessity for 35 procedure codes. 3 other contractor versions share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 116 covered ICD-10-CM codes: the same total as L38240 (Palmetto GBA, 116 codes, revised 2024-11-07) and the same total as L38441 (Wisconsin Physicians Service Insurance Corporation, 116 codes, revised 2026-09-24).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Noridian Healthcare Solutions, LLC
States and territories
16
AK AS AZ CA CNMI GU HI ID MT ND NV OR SD UT WA WY
Revision effective
2026-01-22
Original effective
2020-12-06
Policy text
335 words
Covered ICD-10 codes (articles)
116

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L38331
ContractContractorTypeStates
03201Noridian Healthcare Solutions, LLCA and B MACMT
03301Noridian Healthcare Solutions, LLCA and B MACND
03401Noridian Healthcare Solutions, LLCA and B MACSD
03501Noridian Healthcare Solutions, LLCA and B MACUT
03601Noridian Healthcare Solutions, LLCA and B MACWY
03102Noridian Healthcare Solutions, LLCA and B MACAZ
03202Noridian Healthcare Solutions, LLCA and B MACMT
03302Noridian Healthcare Solutions, LLCA and B MACND
03502Noridian Healthcare Solutions, LLCA and B MACUT
03602Noridian Healthcare Solutions, LLCA and B MACWY
03402Noridian Healthcare Solutions, LLCA and B MACSD
03101Noridian Healthcare Solutions, LLCA and B MACAZ
02201Noridian Healthcare Solutions, LLCA and B MACID
02101Noridian Healthcare Solutions, LLCA and B MACAK
02301Noridian Healthcare Solutions, LLCA and B MACOR
02401Noridian Healthcare Solutions, LLCA and B MACWA
02202Noridian Healthcare Solutions, LLCA and B MACID
02102Noridian Healthcare Solutions, LLCA and B MACAK
02402Noridian Healthcare Solutions, LLCA and B MACWA
02302Noridian Healthcare Solutions, LLCA and B MACOR
01111Noridian Healthcare Solutions, LLCA and B MACCA
01211Noridian Healthcare Solutions, LLCA and B MACAS CNMI GU HI
01311Noridian Healthcare Solutions, LLCA and B MACNV
01911Noridian Healthcare Solutions, LLCA and B MACAS CA CNMI GU HI NV
01112Noridian Healthcare Solutions, LLCA and B MACCA
01182Noridian Healthcare Solutions, LLCA and B MACCA
01212Noridian Healthcare Solutions, LLCA and B MACAS CNMI GU HI
01312Noridian Healthcare Solutions, LLCA and B MACNV

Billing and coding article A57124: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A57124 (Billing and Coding: MolDX: Blood Product Molecular Antigen Typing) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A57124: Billing and Coding: MolDX: Blood Product Molecular Antigen Typing (Billing and Coding, effective 2026-01-22)

Covered ICD-10-CM codes
116
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
35
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A57124
ICD-10-CMDescription (FY2027)
C85.80Other specified types of non-Hodgkin lymphoma, unspecified site
C85.89Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites
C85.90Non-Hodgkin lymphoma, unspecified, unspecified site
C85.91Non-Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck
C85.92Non-Hodgkin lymphoma, unspecified, intrathoracic lymph nodes
C85.93Non-Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes
C85.94Non-Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb
C85.95Non-Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb
C85.96Non-Hodgkin lymphoma, unspecified, intrapelvic lymph nodes
C85.97Non-Hodgkin lymphoma, unspecified, spleen
C85.98Non-Hodgkin lymphoma, unspecified, lymph nodes of multiple sites
C85.99Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites
C90.00Multiple myeloma not having achieved remission
C90.01Multiple myeloma in remission
C90.02Multiple myeloma in relapse
C91.00Acute lymphoblastic leukemia not having achieved remission
C91.01Acute lymphoblastic leukemia, in remission
C91.02Acute lymphoblastic leukemia, in relapse
C92.60Acute myeloid leukemia with 11q23-abnormality not having achieved remission
C92.61Acute myeloid leukemia with 11q23-abnormality in remission
C92.62Acute myeloid leukemia with 11q23-abnormality in relapse
C92.A0Acute myeloid leukemia with multilineage dysplasia, not having achieved remission
C92.A1Acute myeloid leukemia with multilineage dysplasia, in remission
C92.A2Acute myeloid leukemia with multilineage dysplasia, in relapse

Procedure codes: 0001U, 0084U, 0180U, 0181U, 0182U, 0183U, 0184U, 0185U, 0186U, 0187U, 0188U, 0189U, 0190U, 0191U, 0192U, 0193U, 0194U, 0195U, 0196U, 0197U, 0198U, 0199U, 0200U, 0201U, 0221U, 0222U, 81105, 81106, 81107, 81108, 81109, 81110, 81111, 81112, 81403.

Coverage indications, limitations and medical necessity

This policy provides limited coverage for molecular phenotyping of blood product antigens as part of the pre-transfusion evaluation for patients who may require or are expected to require a blood product transfusion(s) (Red Blood Cells [RBCs], Platelets or Leukocytes) when at least one of the following criteria is met:

• Long term, frequent transfusions are anticipated to prevent the development of alloantibodies (e.g., sickle cell anemia, thalassemia, chronic transfusion dependent hematologic disorders or other reasons); OR

• Autoantibodies or other serologic reactivity that impedes the exclusion of clinically significant alloantibodies (e.g. autoimmune hemolytic anemia, warm autoantibodies, patient recently transfused with a positive DAT, high-titer low avidity antibodies, patients about to receive or on daratumumab therapy, other reactivity of no apparent cause); OR

• Suspected antibody against an antigen for which typing sera is not available; OR

• Laboratory discrepancies on serologic typing (e.g., rare Rh D antigen variants)

Laboratory developed tests (LDTs) that perform molecular phenotyping of blood product antigens may be considered covered for the same indications if the test demonstrates validity and clinical utility equivalent to or better than covered tests as demonstrated in a technical assessment.

Medicare does not expect molecular testing to be performed on patients undergoing surgical procedures such as bypass or other cardiac procedures, hip or knee replacements or revisions, or patients with alloantibodies identifiable by serologic testing that are not expected to require long term frequent transfusions. The medical necessity for molecular blood product phenotyping must be documented in the patient’s medical record.

Blood product molecular antigen typing tests are considered germline tests and thus must comply with relevant Medicare or Contractor policies regarding germline testing.

As molecular genotyping includes a review of many genes that code for cellular antigens that must be evaluated for proper patient care, single gene tests are not reasonable and necessary.

If there is a rare instance that a single blood product antigen is reasonable and necessary, its utility must be appropriately documented in the patient’s medical record for validation by medical review.

Summary of evidence (opening)

For patients who require a blood product transfusion, an important step taken prior to the transfusion of any blood product is compatibility testing between the recipient’s serum and the blood product being transfused. In addition to the ABO and Rh system there are 34 other recognized blood group antigen systems by the International Society of Blood Transfusion. 1 Identifying the blood product antigens to which the transfusion recipient will have an immune reaction is a critical component of this compatibility testing, though for most patients identification of ABO and Rh compatibility is sufficient. 2 However, for patients who have alloantibodies or patients who have a predisposition to develop alloimmunization (e.g., patients with sickle cell disease and others who are chronically transfused), compatibility testing of additional systems may be needed. 2,3 Hemagglutination has traditionally been the most common serologic method of determining a blood product phenotype. In this technique, the patient’s RBCs are tested with antisera specific for the antigens of interest. 2,4 However, this method has limitations. It requires direct agglutination typing sera for the antigen, and hemagglutination testing results are not meaningful if a patient has a positive direct antiglobulin test (DAT). 3,4 In addition, serologic phenotyping is likely to be erroneous in the transfused patient who may have persistent donor blood products in circulation, such as patients getting chronic frequent transfusions, and it has been suggested that chronically transfused patients or patients who have had a massive transfusion should not receive phenotyping using serological methods, or that if serological methods are used, they should be confirmed with molecular techniques. 3,5

Because molecular genotyping is not subject to the limitations of conventional serologic testing, the transfusion community has recognized molecular typing as a potential tool to aid in the determination of immune compatibility between donated blood products and the transfusion recipient in a number of circumstances where conventional methods may not be adequate, such as in patients who have a positive direct antigen test, in patients who have been recently transfused or those who are chronically transfused, 6 in patients where a distinction between autoantibodies and alloantibodies is needed, or in situations where the presence of a weakly reactive anti-body is suspected. 2,3,7,8

Prior to broad clinical availability of molecular genotyping in the United States, a number of studies demonstrated both the feasibility of this technique and the incremental information it could provide over serologic typing in limited clinical contexts.

As early as 1999, a study from Germany in patients receiving chronic transfusions demonstrated disparate molecular Rh phenotyping in 7 of 27 patients compared to serologic typing. 9 Soon afterwards, Reid et al 6 demonstrated that Deoxyribonucleic Acid (DNA) from blood samples could be used to genotype patients who had recently been transfused. Castilho et al 10 confirmed the unreliability of serologic testing when they showed that 6 of 40 molecular genotypes differed from serologic phenotypes in multiply transfused sickle cell anemia (SCA) patients 10 , and in 9 of 10 alloimmunized thalassemic patients. 11 A number of investigators have replicated these findings, most notably Bakanay et al 12 when they demonstrated genotypic and phenotypic discrepancies in 19 or 37 multi-transfused patients in multiple alleles. The discrepancies aided in the selection of antigen-matched blood products and improved RBC survival, ultimately improving patient care. A recent case report by Wagner 5 highlighted the practical utility of molecular testing over serologic testing for chronically transfused patients.

The contractor cites 24 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2020-12-06
Current revision effective
2026-01-22
Last reviewed by the contractor
2024-09-19
MCD version
25

Other related documents: A58505 (Response to Comments), A58506 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Noridian Healthcare Solutions, LLC hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L38331 cover?

This policy provides limited coverage for molecular phenotyping of blood product antigens as part of the pre-transfusion evaluation for patients who may require or are expected to require a blood product transfusion(s) (Red Blood Cells [RBCs], Platelets or Leukocytes) when at least one of the following criteria is met: The full 335-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L38331 apply to?

Noridian Healthcare Solutions, LLC applies it to Medicare claims in 13 states plus 3 territories: AK, AS, AZ, CA, GU, HI, ID, MP, MT, ND, NV, OR, SD, UT, WA, WY. It binds only that contractor; 3 other contractor versions of this title govern other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L38331?

The companion billing and coding article A57124 lists 116 ICD-10-CM codes in 1 group that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L38331?

A denial under LCD L38331 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A57124's 116 covered diagnosis codes, then file a redetermination with Noridian Healthcare Solutions, LLC within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.